Impact of adding bevacizumab to presurgery chemo for triple-negative breast cancer varies with subtype

Share this content:
Impact of adding bevacizumab to presurgery chemo for triple-negative breast cancer varies with subty
Impact of adding bevacizumab to presurgery chemo for triple-negative breast cancer varies with subty
Among women with triple-negative breast cancer, the benefit of adding bevacizumab to standard presurgery chemotherapy was greater for those whose cancers were classified as basal-like by gene expression assay compared with those whose cancers were nonbasal-like, according to data presented at the 2014 San Antonio Breast Cancer Symposium, held Dec.
READ FULL ARTICLE From Medical Express
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




is free, fast, and customized just for you!




Already a member?

Sign In Now »